Pre-MEASURE: Retrospective Analysis of the Prognostic Significance of NGS-MRD Testing in Patients With AML in First Remission Prior to Allogeneic HCT

June 3-7, 2022; Chicago, Illinois
In this retrospective analysis of CIBMTR-collected blood samples, NGS-MRD detection of NPM1 mutations and/or FLT3-ITD was associated with significant prognostic value for relapse and survival in patients with AML in first remission prior to allogeneic HCT.
Format: Microsoft PowerPoint (.ppt)
File Size: 159 KB
Released: June 17, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seattle Genetics

Related Content

Commentary on the evolving therapeutic landscape in peripheral T-cell lymphomas with a focus on EZH1/2 inhibition, from Clinical Care Options (CCO)

Steven M. Horwitz, MD
Program Director
Pamela B. Allen, MD Pierluigi Porcu, MD
Released: August 8, 2022

Video featuring Jesús Berdeja, MD, and Sagar Lonial, MD, discussing the latest evidence on approved and investigational CAR T-cell therapies for multiple myeloma, from Clinical Care Options (CCO)

Jesús G. Berdeja, MD Sagar Lonial, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 5, 2022 Expired: August 4, 2023

Expert webcast recording of live webinar on selecting therapy and managing toxicities for indolent B-cell lymphomas, from Clinical Care Options (CCO)

Elizabeth Brém, MD
Program Director
Christopher R. Flowers, MD, MS
Program Director
person default Pallawi Torka, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 3, 2022 Expired: August 2, 2023

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

person default Othman Al-Sawaf, MD Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: July 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings